Deferred treatment of clinically localized low grade prostate cancer: the experience from a prospective series at the Karolinska Hospital.
From 1978 to 1982, 172 patients with stages T1 to 3NxM0 prostate cancer were included in a surveillance protocol with deferred treatment on symptomatic progression. Median patient age at diagnosis was 68 years (range 38 to 89 years). Mean followup was 80 +/- 32 months. Of the patients 58% had local and 19% had distant progression, and 52% had received treatment at followup. Disease specific survival rate at 10 years was 80% for the total series, 84% for the subgroup with stage T1 or T2 tumor and 92% for those with stage T1 or T2 tumor who were less than 70 years old at diagnosis. For the subgroup with stage T3 tumor the disease specific survival rate at 9 years was 70%. In all subgroups the competing mortality rate was higher than the prostate cancer mortality rate. Deferred treatment appears to be an acceptable option for patients with tumor clinically confined to the prostate and a life expectancy of 10 years or less.
Adolfsson
J
J
Department of Urology, Karolinska Hospital, Stockholm, Sweden.
Rönström
L
L
Löwhagen
T
T
Carstensen
J
J
Hedlund
P O
PO
D000135:Acid Phosphatase / Q000032:analysis; D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002423:Cause of Death; D018450:Disease Progression; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011159:Population Surveillance; D011446:Prospective Studies; D011467:Prostate / Q000201:enzymology; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D013548:Sweden
D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen